



LucidQuest Intelligence
Accelerate your success



AAD 2025 Preview – Table of Contents

• <u>General Overview and Conference Themes</u>	<u>3-5</u>
• <u>Noteworthy Scientific presentations at AAD'25</u>	<u>6-58</u>
• <u>Key Topics From Notable Presentations</u>	<u>7-9</u>
• <u>Focus of Key Sponsored Symposia Information at AAD'25</u>	<u>10-13</u>
• <u>Late Breakers & Notable Presentations Information</u>	<u>14-47</u>
• <u>Key Sponsored Symposia Information</u>	<u>48-58</u>
• <u>Noteworthy AI / ML Presentations</u>	<u>59-67</u>
• <u>Key AI / ML Themes</u>	<u>60-61</u>
• <u>Key AI/ML Presentations Information</u>	<u>62-67</u>
• <u>Get in touch with LucidQuest</u>	<u>68</u>



AAD 2025 – General Overview

- ➔ • **Innovative Therapies:** Experts will unveil advancements in biologics and small molecules for psoriasis, atopic dermatitis, and hidradenitis suppurativa
- ➔ • **Patient-Centered Care:** Emphasis will be on real-world data to refine treatment strategies and improve outcomes
- ➔ • **Digital Dermatology:** Experts will explore the role of artificial intelligence and teledermatology in enhancing diagnostic accuracy and patient management
- ➔ • **Precision Dermatology:** The focus will be on genomic insights and personalized treatments for complex skin disorders
- ➔ • **Environmental Impact on Skin Health:** Updates on emerging research on pollution, climate change, and their effects on inflammatory and autoimmune skin diseases
- ➔ • **Industry-Academic Synergy and Global Collaboration:** New partnerships between academia, industry, and international experts will be showcased to accelerate dermatology research and develop unified approaches to disease management from bench to bedside



AAD 2025– Conference Themes (1/2)



- **Advanced Immunotherapies:** Advances on novel immune modulators targeting cytokine pathways to manage chronic inflammatory skin diseases more effectively
- **Artificial Intelligence Integration:** Sessions will explore AI-based diagnostic tools, predictive analytics, and personalized treatment pathways to enhance clinical decision-making in dermatology
- **Pediatric Dermatology Advances:** Updates on new biologics and small molecules targeting eczema, psoriasis, and rare genetic disorders in pediatric populations
- **Teledermatology Evolution:** The focus will be on optimizing virtual care models, overcoming regulatory challenges, and integrating AI for remote diagnostics and follow-ups
- **Microbiome Research:** Emerging studies set to highlight the role of skin microbiota in modulating inflammation and preventing infections in conditions like acne and eczema



AAD 2025– Conference Themes (2/2)



- **Phototherapy Innovations:** Latest advancements in targeted phototherapy, including excimer lasers and narrowband UVB, for treating psoriasis, vitiligo, and atopic dermatitis
- **Cutaneous Oncology:** Sessions will cover breakthroughs in immunotherapy, early diagnostic markers, and personalized treatment options for melanoma and non-melanoma skin cancers
- **Regenerative Dermatology:** Focus on stem cell therapies, tissue engineering, and growth factors for wound healing, scarring, and skin rejuvenation
- **Ethnic Skin Disorders:** Addressing disparities in diagnosis and treatment of pigmentary disorders and keloids among diverse populations through culturally sensitive approaches
- **Health Policy and Advocacy:** Strategies to influence dermatology-related policies, improve insurance coverage, and enhance patient access to advanced treatments

Noteworthy Scientific presentations at AAD 2025





Key Topics From Notable Presentations (1/3)

- ✓ • **Inflammatory Skin Diseases and Immunotherapy:** Presentations will explore the efficacy of JAK inhibitors and biologics in managing conditions like psoriasis and atopic dermatitis. Key studies will explore Remibrutinib impact on CSU symptoms and Bimekizumab role in maintaining clinical responses in axial spondyloarthritis over multi-year trials
- ✓ • **Hidradenitis Suppurativa (HS) Studies:** The focus will be on novel therapies like Bimekizumab and Vilobelimab for HS management. Trials will address pain management, reduction of draining tunnels, and the role of microbiome diversity in disease progression and treatment response in HS patients
- ✓ • **Atopic Dermatitis (AD) and JAK Inhibitors:** Emphasis will be on JAK inhibitors and biologics in AD treatment, highlighting abrocitinib's efficacy in relieving pruritus and ruxolitinib cream's long-term safety. Results will also examine infection risks and the impact of dupilumab on skin barrier function



Key Topics From Notable Presentations (2/3)

- ✓ • **Psoriasis and Comorbidities:** Sessions are set to highlight cardiovascular risks and long-term outcomes of biologics for psoriasis. Key studies will assess IL-23 inhibitors' impact on comorbidities and the long-term safety of risankizumab in managing moderate-to-severe psoriasis, focusing on cardiovascular and metabolic health
- ✓ • **Dermatologic Oncology and Skin Cancers:** Early detection and personalized treatments for melanoma and actinic keratosis will be discussed. FDG-PET's role in melanoma staging and the efficacy of tirbanibulin in managing actinic keratosis, emphasizing survival outcomes and recurrence prevention will be highlighted
- ✓ • **Alopecia Areata and Hair Disorders:** Presentations will cover emerging treatments like deuruxolitinib and minoxidil, focusing on patient-reported outcomes. Key trials will explore the effectiveness of minoxidil formulations and the long-term safety and efficacy of Ritlecitinib in severe alopecia areata



Key Topics From Notable Presentations (3/3)

- ✓ • **Cosmetic and Aesthetic Dermatology:** Focus will be on anti-aging treatments and injectables, emphasizing safety and efficacy. Use of hyaluronic acid fillers for midface rejuvenation and the efficacy of polynucleotides in facial and neck lifting, highlighting patient satisfaction will be discussed
- ✓ • **Health Disparities and Access to Care:** Sessions will address disparities in care access based on race, ethnicity, and geography. Key studies will highlight gaps in dermatology trial representation and disparities in access to advanced treatments for inflammatory conditions, focusing on underserved populations
- ✓ • **Environmental and Lifestyle Impact on Skin Health:** Presentations will explore how environmental and lifestyle factors influence skin conditions. Key studies will discuss UVB phototherapy's protective effects against cardiometabolic diseases and the impact of early-life diet on atopic dermatitis outcomes, highlighting preventive strategies



Focus of Key Industry Sponsored Symposia at AAD 2025 (1/4)

- **LEO Pharma:**

- Focus Areas: Chronic Hand Eczema Treatment
- Discussions will emphasize novel approaches to managing chronic hand eczema, exploring new treatments and their efficacy in enhancing patient outcomes

- **Beiersdorf:**

- Focus Areas: Dark Spot Correction Innovations
- Discussion on “THIAMIDOL: A Breakthrough Innovation in Dark Spot Correction” will cover novel mechanisms and clinical efficacy of THIAMIDOL in addressing hyperpigmentation

- **Medscape / AbbVie:**

- Focus Areas: Psoriasis Management and Atopic Dermatitis
- Multiple sessions, including “Inside Psoriasis,” “Segment 1–5,” and “Elevating Care in Moderate to Severe Atopic Dermatitis,” will explore advanced systemic therapies, clinical responses, and challenges in managing psoriasis and atopic dermatitis



Focus of Key Industry Sponsored Symposia at AAD 2025 (2/4)

- **Pfizer:**

- Focus Areas: **Vitiligo Pathogenesis and Patient Experience**
- Discussions **will highlight patient experiences and emerging therapies for vitiligo**, focusing on improving quality of life and treatment outcomes

- **Eli Lilly:**

- Focus Areas: **Biologics in Atopic Dermatitis**
- Sessions will **delve into biologic treatments for atopic dermatitis, clarifying mechanisms and optimizing therapy pathways** for better disease management

- **Johnson & Johnson:**

- Focus Areas: **Addressing Unmet Needs in Psoriasis**
- “The Patient’s Voice: Guiding the Path to Address Unmet Needs in Psoriasis” will **emphasize patient-centered approaches** and novel treatment strategies for psoriasis



Focus of Key Industry Sponsored Symposia at AAD 2025 (3/4)

- **Sanofi / Regeneron:**

- Focus Areas: Type 2 Immunity in Dermatologic Conditions
- Comprehensive discussions will cover the impact of Type 2 inflammation on dermatologic conditions and the potential of immunotherapies in managing chronic skin diseases

- **Regeneron:**

- Focus Areas: Immunotherapy in Nonmelanoma Skin Cancer
- Multiple sessions, will highlight strategies for integrating neoadjuvant immunotherapy in nonmelanoma skin cancers, focusing on efficacy, safety, and multidisciplinary approaches

- **Sanofi:**

- Focus Areas: OX40-Ligand Pathway in Atopic Dermatitis
- “Atopic Dermatitis Pathway Pursuit: The OX40-Ligand Edition” will delve into targeting the OX40-Ligand pathway for enhanced management of atopic dermatitis



Focus of Key Industry Sponsored Symposia at AAD 2025 (4/4)



- **Blueprint Medicines:**

- Focus Areas: [Systemic Mastocytosis Diagnosis and Management](#)
- Presentations will explore [emerging treatments for systemic mastocytosis](#), focusing on patient management and therapeutic advancements



Late Breakers and Notable Presentations Information at AAD 2025

Late Breakers and Notable Presentations Information at AAD '25

Inflammatory Skin Diseases and Immunotherapy (1/6)

Date	Author	Title
07 Mar 2025	Andrea Caro Muniz	Epidemiology of Atopic Dermatitis in Puerto Rico: a Retrospective, Single-Center Study
07 Mar 2025	Alexa Kassels	Lichen sclerosus is associated with the atopic triad: A retrospective population-level study
07 Mar 2025	Henry Herrera	Association Between Hidradenitis Suppurativa and New-Onset Inflammatory Arthropathies: A Retrospective Population-Based Cohort Study
07 Mar 2025	Sonja Ständer	Characterization of the pruriginous lesion types in individuals with prurigo nodularis and efficacy from the randomized, placebo-controlled, Phase 3 OLYMPIA 1&2 trials
07 Mar 2025	Hannah Verma	The Relationship between Psoriasis, Treatment Type, and Subsequent Non-Alcoholic Steatohepatitis: A Global TriNetX Database Study
07 Mar 2025	Marina Mordehachvili Burlá	Janus Kinase and Tyrosine Kinase Inhibitors for Hidradenitis Suppurativa: a Meta-Analysis of Randomized Controlled Trials
07 Mar 2025	Robert Snyder	Effect of Remibrutinib on Sleep and Daily Activities in Patients With Chronic Spontaneous Urticaria (CSU) up to Week 52 in the REMIX-1/-2 studies

Late Breakers and Notable Presentations Information at AAD '25

Inflammatory Skin Diseases and Immunotherapy (2/6)

Date	Author	Title
07 Mar 2025	Alice B. Gottlieb	Maintenance of stringent clinical responses with bimekizumab in patients with axial spondyloarthritis: 2-year outcomes from two phase 3 studies
07 Mar 2025	Amy Paller	Baseline Growth Analysis of Children and Adolescents With Moderate-to-Severe Atopic Dermatitis Enrolled in Phase 3 Dupilumab Trials
07 Mar 2025	Zakiya P. Rice	Improvements in Sleep and Pruritus With Abrocitinib Versus Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the JADE DARE Study
07 Mar 2025	Maria Schneeweiss	Serious infections in patients with atopic dermatitis who started a JAK-inhibitor vs. cytokine-inhibitor: a nationwide propensity-score matched cohort study
07 Mar 2025	John Frdew MBBS	Gender Influences Clinical Response to Guselkumab in Hidradenitis Suppurativa: A post-hoc analysis of Phase 2 Individual Patient Data
07 Mar 2025	Joseph McGrath	The Use of Perineural Invasion Score as a Predictor for Adverse Events in Patients with Cutaneous Squamous Cell Carcinoma: A Validation Study
07 Mar 2025	Amy Paller	Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 2-year results from the SPROUT extension trial

Late Breakers and Notable Presentations Information at AAD '25

Inflammatory Skin Diseases and Immunotherapy (3/6)

Date	Author	Title
07 Mar 2025	Shannon Wessel	<u>TNF-a, IL-1, and JAK Inhibitors Associated with Increased Reporting Odds of Coccidioidomycosis: A Pharmacovigilance Study of FDA Adverse Event Reporting System</u>
07 Mar 2025	Jeffrey Crowley	<u>Impact of High Skin Clearance on Psychosocial Outcomes and Symptoms Associated With Psoriasis: Pooled Results From the UltIMMa 1 & 2 Studies</u>
08 Mar 2025	Mark Lebwohl	<u>Bimekizumab achievement of 'super response' using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials</u>
08 Mar 2025	Hannah Verma	<u>The Relationship between Inflammatory Bowel Disease, Biologic Treatment, and Subsequent Hidradenitis Suppurativa Diagnosis: A Global TriNetX Database Study</u>
08 Mar 2025	David Garate	<u>Risk of Venous Thromboembolism in Patients with Vitiligo and Alopecia Areata: A Large Population-Based Cohort Study</u>
08 Mar 2025	Alexandra Nigro.	<u>Increased adverse reproductive, maternal, and pregnancy-related outcomes among female patients with hidradenitis suppurativa compared to the general population: A propensity-score matched global study of 31,426 female patients.</u>
08 Mar 2025	Andrew Alexis	<u>Efficacy of Abrocitinib in Improving Signs of Atopic Dermatitis by Body Location in Patients With Moderate-to-Severe Atopic Dermatitis: Results From JADE DARE</u>

Late Breakers and Notable Presentations Information at AAD '25

Inflammatory Skin Diseases and Immunotherapy (4/6)

Date	Author	Title
08 Mar 2025	Zhixiao Wang	Sustained Disease Control Among Adults with Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 5-Year Follow-up Results From the RELIEVE-AD Study
08 Mar 2025	Maria Schneeweiss	Increased risk of herpes infections in patients with atopic dermatitis who started a JAK-inhibitor vs. Th2 cytokine-inhibitor: a propensity-score matched claims data study
08 Mar 2025	Afsaneh Alavi	Vilobelimab Safety in Pyoderma Gangrenosum Patients: A Phase 2a Explorative Dose-Finding Study
08 Mar 2025	Anjana Srikumar	Racial Disparities in the Misdiagnosis of Dermatofibrosarcoma Protuberans: A Retrospective Cohort Study
08 Mar 2025	Benjamin Hu	Comparing Merkel Cell Carcinoma Survival Outcomes by Metropolitan, Suburban, and Rural Residence: An Analysis Using the Surveillance, Epidemiology, and End Results (SEER) Database
08 Mar 2025	Shawn Kwatra	Efficacy and Safety of Ruxolitinib Cream in Patients With Prurigo Nodularis: Results From a Phase 3, Randomized, Vehicle-Controlled Study (TRuE-PN1)
08 Mar 2025	Andrew Blauvelt	Efficacy and safety of ESK-001, a highly selective oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis: long term Phase 2 results

Late Breakers and Notable Presentations Information at AAD '25

Inflammatory Skin Diseases and Immunotherapy (5/6)

Date	Author	Title
08 Mar 2025	Emma Guttman	Rocatinlimab Significantly Improved Clinical Signs and Symptoms by Targeting OX40R+ T cells in Patients with Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 ROCKET HORIZON Trial
08 Mar 2025	Ling Zhang	Efficacy and Safety of a Novel TYK2 Inhibitor D-2570 in Patients with Moderate to Severe Plaque Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
08 Mar 2025	Martin Metz	Briquilimab demonstrates rapid, clinically meaningful reduction in disease activity in adults with chronic spontaneous urticaria (CSU): Results from a Phase 1b/2a study
08 Mar 2025	Frederic Caux	Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid: Results From LIBERTY-BP ADEPT Phase 2/3 Study
08 Mar 2025	Melinda Gooderham	Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-to-Target, Multi-Center Phase...
08 Mar 2025	Mary C. Spellman	PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: Interim Results from an Ongoing Study of INTASYL PH-762
08 Mar 2025	Thierry Passeron	Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 36-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial

Late Breakers and Notable Presentations Information at AAD '25

Inflammatory Skin Diseases and Immunotherapy (6/6)

Date	Author	Title
09 Mar 2025	Brett King	Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
09 Mar 2025	Zachary A. Zinn	Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study
09 Mar 2025	Henry Herrera	Impact of Secukinumab, Adalimumab, and Infliximab Treatments on Hidradenitis Suppurativa Related Emergency Department Visits: A Retrospective Cohort Study

Late Breakers and Notable Presentations Information at AAD '25

Hidradenitis Suppurativa (HS) Studies (1/4)

Date	Author	Title
08 Mar 2025	Kelly Young	Analysis of patients with hidradenitis suppurativa from a large, single-center Detroit cohort: a retrospective cross-sectional study of 13,130 patients over a 27-year period
08 Mar 2025	Ruby Gibson	An Exploratory Study to Assess the Microbiome Composition and Diversity in Hidradenitis Suppurativa Skin Lesions
09 Mar 2025	Raveena Ghanshani	Dissecting cellulitis of the scalp and HS: A retrospective study of 106 patients
Throughout	Raj Chovatiya	Bimekizumab efficacy by disease duration in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT
Throughout	Christopher J. Sayed	IHS4-100 responses and other IHS4 outcomes with the IL-17A- and IL-17F-inhibiting Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial
Throughout	Rayad Shams	Intralesional Gentamicin for the treatment of Hidradenitis Suppurativa: A Real-World Efficacy Study
Throughout	Albert T. Young	Adherence to Breast Cancer Screening Guidelines Among Patients with Hidradenitis Suppurativa: A Retrospective Cohort Study

Late Breakers and Notable Presentations Information at AAD '25

Hidradenitis Suppurativa (HS) Studies (2/4)

Date	Author	Title
Throughout	Christopher J. Sayed	Bimekizumab efficacy by patient subgroups in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT
Throughout	Lauren A.V. Orenstein	Bimekizumab effect on pain severity and impact in moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT
Throughout	John R. Ingram	Bimekizumab safety and tolerability in patients with moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT
Throughout	Alexa B. Kimball	Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II
Throughout	Sarah Schultz	The Incidence of Hematologic Malignancies in Patients with Hidradenitis Suppurativa: An Institutional Study
Throughout	Adam Friedman	Persistence and Adherence Among Patients with Chronic Spontaneous Urticaria Initiating Advanced Therapies: A Real-World, Claims Database Study
Throughout	Thrasyvoulos Tzellos	Bimekizumab impact on draining tunnel reduction over 2 years in moderate to severe hidradenitis suppurativa: Results from BE HEARD EXT

Late Breakers and Notable Presentations Information at AAD '25

Hidradenitis Suppurativa (HS) Studies (3/4)

Date	Author	Title
Throughout	Helana Ghali	Psychiatric Symptoms and Utilization of Support Resources in Hidradenitis Suppurativa Patients: A Cross-Sectional Study
Throughout	Alexa B Kimball	Remibrutinib in patients with moderate to severe hidradenitis suppurativa: Patient reported outcomes from a randomized, phase 2, double-blind, placebo-controlled platform study
Throughout	Martina L. Porter	Resolution of deep dermal inflammatory lesions with the Nanobody sonelokimab in moderate-to-severe hidradenitis suppurativa (HS): preclinical results and outcomes from the Phase 2 MIRA trial
Throughout	Jennifer Hsiao	The impact of continuous secukinumab treatment between weeks 52–104 on draining tunnels in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE extension trial
Throughout	Afsaneh Alavi	Efficacy of secukinumab uptitration from every 4 weeks to every 2 weeks dosing between weeks 52–104 in week 52 HiSCR non-responder patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE extension trial
Throughout	Evangelos Giamarellos-Bourboulis	Reduction in Draining Tunnels in Hidradenitis Suppurativa Patients Treated with Vilobelimab in a Randomized, Placebo-Controlled, Double-Blind Multicenter Phase 2b Study
Throughout	Evangelos Giamarellos-Bourboulis	Vilobelimab Post-hoc Efficacy in Hidradenitis Suppurativa using the Modified-HiSCR with Data from the Phase 2b SHINE Study

Late Breakers and Notable Presentations Information at AAD '25

Hidradenitis Suppurativa (HS) Studies (4/4)

Date	Author	Title
Throughout	Evangelos Giamarellos-Bourboulis	Vilobelimab Safety in Hidradenitis Suppurativa Patients in a Randomized, Placebo-Controlled, Double-Blind Multicenter Phase 2b study
Throughout	Camille Basurto	A Retrospective Study of Hospitalization Rates in Hidradenitis Suppurativa Patients
Throughout	Maria Cinta Sin i Soler	Retrospective study of 32 pediatric patients with hidradenitis suppurativa and down syndrome.

Late Breakers and Notable Presentations Information at AAD '25

Atopic Dermatitis and JAK Inhibitors (1/3)

Date	Author	Title
07 Mar 2025	John Kelly	Patient-Level Clinical Response Rates to GSK1070806, an Anti-IL-18 Monoclonal Antibody, in Moderate-to-Severe Atopic Dermatitis (AD): A Randomized, Double-Blind, Placebo-Controlled Study
08 Mar 2025	Ayu Watanabe	Incidences of herpes zoster and acne by age in Japanese patients with atopic dermatitis during treatment with baricitinib or upadacitinib: A single-center retrospective study
08 Mar 2025	Jianhui Li	QY201 in adults with moderate-to-severe atopic dermatitis: 12-week results from a dose-finding phase 2 trial
08 Mar 2025	Jianzhong Zhang	Efficacy and safety of ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of adult with severe alopecia areata (AA): a randomized, double-blind, placebo-controlled phase 3..
Throughout	Leon Kircik	Ruxolitinib Cream Demonstrated Long-Term Disease Control and Quality of Life Benefits in Adults and Adolescents With Mild to Moderate Atopic Dermatitis
Throughout	Rafaela de Moraes-Souza	Efficacy and Safety of Topical Delgocitinib for Chronic Hand Eczema: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Throughout	Lawrence F. Eichenfield	52-Week Disease Control and Safety With As-Needed Application of Ruxolitinib Cream in Children Aged 2 to 11 Years With Moderate and/or More Extensive Atopic Dermatitis: Subgroup Analysis From the TRuE-AD3 Study

Late Breakers and Notable Presentations Information at AAD '25

Atopic Dermatitis and JAK Inhibitors (2/3)

Date	Author	Title
Throughout	Christopher Bunick	Rapid Itch Relief with Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3b/4 Level Up Study
Throughout	Linda Stein Gold	Tapinarof Cream 1% Once Daily for Atopic Dermatitis: Validated Investigator Global Assessment for Atopic Dermatitis™ x Body Surface Area (vIGA-AD™xBSA) Composite in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age
Throughout	Liuqing Chen	Early response to Ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of a phase III trial
Throughout	Qingchun Diao	Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with prior systemic therapy: a post-hoc analysis of a phase III trial
Throughout	Jinhua Xu	Ivarmacitinib in patients with moderate-to-severe atopic dermatitis, stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial
Throughout	Lunfei Liu	Effects of ivarmacitinib on itch and sleep improvements and their impact on quality of life in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of a phase III trial
Throughout	Robert Bissonnette	Dupilumab Treatment Improves Skin Barrier Function in Adolescent and Adult Patients With Atopic Dermatitis: Results From the BALISTAD and BALISTAD-CN Studies

Late Breakers and Notable Presentations Information at AAD '25

Atopic Dermatitis and JAK Inhibitors (3/3)

Date	Author	Title
Throughout	Zhixiao Wang	Dupilumab Improves Health-Related Quality of Life and Work Productivity Among Adults With Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 5-Year Follow-up Results From the RELIEVE-AD Study
Throughout	Kilian Eyerich	Impact on Multiple Inflammatory Axes Drives a High Level of Efficacy to Upadacitinib: Biomarker Analysis from LEVEL-UP, a Phase 3b/4 Head-to-Head Study with Dupilumab
Throughout	Michele Ramien	Dupilumab Improves Patient-Reported Outcomes in Patients of Color Aged Less Than 12 Years With Atopic Dermatitis: 4-Year Results From the PEDISTAD Registry
Throughout	Eric L. Simpson	Long-Term Safety of Ruxolitinib Cream in Adults and Adolescents With Mild-to-Moderate Atopic Dermatitis: Adverse Events of Interest From the TRuE-AD1 and TRuE-AD2 Phase 3 Studies
Throughout	Jinan Liu	Association of Ruxolitinib Cream Initiation With Reduction in Use of Other Topical Treatments, Oral Corticosteroids, and Biologics for Atopic Dermatitis, Regardless of Previous Use of Biologics
Throughout	Brian Kim	Impact of amlitelimab (an anti-OX40 Ligand antibody) on maintenance of itch response in atopic dermatitis: results from the 52-week STREAM-AD Phase 2b study
Throughout	Diamant Thaçi	Interim results of RIVER-AD: 28-week open-label safety and efficacy of amlitelimab in patients with atopic dermatitis not initially achieving clinical response at Week 24 of the STREAM-AD phase 2b trial

Late Breakers and Notable Presentations Information at AAD '25

Psoriasis and Comorbidities (1/3)

Date	Author	Title
07 Mar 2025	Aman Sandhu	Global PROBE – Project for Revealing Online Bias and Exploration - an Online Survey to Examine Psoriasis Search Results
07 Mar 2025	Ana Ormaza Vera	Psoriasis treatment with interleukin-23 inhibitors associates with lower likelihood of modifiable cardiovascular risk factors compared to treatment with other biologics: A retrospective cohort study using real-world data.
08 Mar 2025	Joseph F Merola	Comorbidity burden and demographics of patients across subtypes of CLE from a large US electronic health record database study
08 Mar 2025	Caitlin Kearney	Characterization of patient preferences and barriers to education on cardiometabolic risk in psoriasis: a quality improvement survey study.
Throughout	Jan Wagner	Monitoring Costs in Psoriasis: Insights from a Large-Scale Retrospective Study
Throughout	Steven R. Feldman	Moderate to severe scalp psoriasis is associated with severe impact on quality of life: an analysis of patient-reported outcomes in PSORIATYK SCALP, a scalp-specific phase 3b/4 trial with deucravacitinib
Throughout	Steven R. Feldman	Deucravacitinib is associated with improvements in Dermatology Life Quality Index in patients with moderate to severe scalp psoriasis: an analysis of PSORIATYK SCALP, a randomized, double-blind, placebo-controlled, phase 3b/4 trial

Late Breakers and Notable Presentations Information at AAD '25

Psoriasis and Comorbidities (2/3)

Date	Author	Title
Throughout	Andrew Blauvelt	Impact of ixekizumab on mental health in adult patients with psoriasis: updated integrated analysis of clinical trial and real-world data
Throughout	Sascha Gerdes	Guselkumab demonstrates effectiveness regardless of disease duration: Week 76 results from the real-world G-EPOSS study
Throughout	Kenneth B. Gordon	Integrated Interval Analysis of Clinical Trial Data to Evaluate the Long-Term Safety of Risankizumab in Patients With Psoriatic Disease
Throughout	Kilian Eyerich	Pharmacokinetics of guselkumab in super-responders and long-term psoriasis disease control: insights from the Phase 3b GUIDE trial
Throughout	Nada Elbuluk	Zasocitinib (TAK-279), an oral, allosteric, selective TYK2 inhibitor, in moderate-to-severe plaque psoriasis: efficacy analysis by baseline characteristics from a randomized phase 2b trial
Throughout	April W. Armstrong	Long-Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response in Patients with Moderate to Severe Psoriasis Treated with Risankizumab: 3 Year Results from the CorEvitas Psoriasis Registry
Throughout	Howard L Sofen	Efficacy and safety of tildrakizumab for the treatment of obese patients with moderate-to-severe plaque psoriasis affecting the scalp: Post hoc analysis of a Phase 3b trial

Late Breakers and Notable Presentations Information at AAD '25

Psoriasis and Comorbidities (3/3)

Date	Author	Title
Throughout	Matthias Augustin	Secukinumab demonstrates high retention and favorable safety in patients with moderate to severe plaque psoriasis: Five-year results from the real-world SERENA study
Throughout	Alice B. Gottlieb Clinical Professor of Dermatology	Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 2-year results from two phase 3 studies
Throughout	Yoshiki Okada	Effectiveness and safety of spesolimab in patients with generalized pustular psoriasis: A single-center retrospective study
Throughout	Bruce Strober	Incidence of Psoriatic Arthritis in Biologic-Naïve Psoriasis Patients Achieving National Psoriasis Foundation's Treat to Target Goals: A Real-World Study With the CorEvitas Psoriasis Registry
Throughout	April Armstrong	Bimekizumab efficacy in patients with psoriasis and concurrent hypertension, elevated body mass index, or hyperglycemia: Long-term results from BE BRIGHT
Throughout	Lourdes Rodriguez Fernandez Freire	Efficacy and pharmacoeconomic analysis in real clinical practice conditions of patients with plaque psoriasis treated with Guselkumab: A single-centre retrospective study over 208 weeks
Throughout	Xiaoguang Zhang	Impact of vunakizumab on metabolic parameters and body mass index in moderate-to-severe plaque psoriasis patients with or without comorbidities: a post-hoc analysis of a phase III trial

Late Breakers and Notable Presentations Information at AAD '25

Dermatologic Oncology and Skin Cancers (1/4)

Date	Author	Title
07 Mar 2025	Devin Barzallo	Comparative Diagnostic Accuracy Study of AI Chatbots in Diagnosing Skin Cancer Subtypes
07 Mar 2025	Emily Wenande	The VAXAK Study: Impact of human papillomavirus vaccination on burden of disease in patients with actinic keratosis - a randomized controlled trial
07 Mar 2025	Michael Ong	Comparative outcomes of sebaceous carcinomas in Muir-Torre Syndrome vs. sporadic cases: a retrospective study
07 Mar 2025	Amit Pandya	TONE Post-Approval Study: Repigmentation Response of Stable Vitiligo Lesions Following Autologous Skin Cell Suspension Treatment Prepared by a Point-of-Care Cell Harvesting Device
09 Mar 2025	Emily S Ruiz	Most cutaneous squamous cell carcinoma recurrences occur in the first 3 years after diagnosis: A multicenter retrospective cohort study
09 Mar 2025	Dominga Peirano	Role of FDG-PET in Early-Stage Melanoma staging and follow-up: A retrospective study
09 Mar 2025	Jose W. Ricardo	Low incidence of oral squamous cell carcinoma in patients with oral lichen planus on sustained anti-inflammatory therapy: A single-center retrospective study of 273 patients

Late Breakers and Notable Presentations Information at AAD '25

Dermatologic Oncology and Skin Cancers (2/4)

Date	Author	Title
Throughout	Neal Bhatia	Clearance of actinic keratosis (AK) with tirbanibulin: Comparing results from controlled trials with real-world clinical studies
Throughout	Todd Schlesinger	Patient outcomes and satisfaction with tirbanibulin for the treatment of actinic keratosis (AK): Results from post-registration studies
Throughout	Andrew Blauvelt	Safety and tolerability of tirbanibulin for the treatment of actinic keratosis (AK): Results from clinical trials and post-registration
Throughout	Afsaneh Alavi	Pharmacokinetic/Pharmacodynamic Analysis of Vilobelimab and Complement C3 and C5a in a Randomized, Controlled Multidose Phase 2a Study in Pyoderma Gangrenosum
Throughout	Alina Markova	Axatilimab for Patients With Dermatologic Manifestations of Chronic Graft-Versus-Host Disease: A Post Hoc Analysis
Throughout	Tsuyoshi Mitsuishi	Safety and Efficacy of TO-208 in Japanese Children and Adults with Molluscum Contagiosum: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
Throughout	Caroline Raymundo	Generation of Concepts for a Core Domain Set to Assess Health-Related Quality of Life in Patients with Cutaneous T-Cell Lymphoma: a Mixed Methods Study

Late Breakers and Notable Presentations Information at AAD '25

Dermatologic Oncology and Skin Cancers (3/4)

Date	Author	Title
Throughout	Keon Niknejad	Cardiovascular Safety and Survival Outcomes of Phototherapy in Cutaneous T-Cell Lymphoma: A Multicenter Retrospective Cohort Study
Throughout	Viviane Liao	Diagnosis of cutaneous T-cell lymphoma following exposure to dupilumab and JAK-inhibitors: retrospective cohort study from a single tertiary cancer center
Throughout	Henry Herrera	Disparities in the Treatment of Melanoma in Situ: A Retrospective Population-Based Cohort Study
Throughout	Laura Vieira Medical Student	Geographic Access to Melanoma Clinical Trials
Throughout	Benjamin Hu	Relative Survival of Melanoma Subtypes and Merkel Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database
Throughout	Marianne Tissot	The Correlation of Reflectance Confocal Microscopy with Dermoscopic Patterns in Pathologically Confirmed Spitz Nevi: A Descriptive Study of 41 Lesions
Throughout	Omar Alani ScB	A Nationwide Study on the Post-Pandemic Rise of Thick Melanomas in Women: Skin Cancer Incidence During the COVID-19 Period

Late Breakers and Notable Presentations Information at AAD '25

Dermatologic Oncology and Skin Cancers (4/4)

Date	Author	Title
Throughout	Eva Shelton	Wound Complications Following Cutaneous Surgery in Solid Organ Transplant Recipients on Sirolimus vs. Tacrolimus: A Retrospective Study
Throughout	Urmila Sivagnanalingam	Exploring the relationship between belatacept use and time to first cutaneous squamous cell carcinoma among transplant patients: a single-center retrospective study
Throughout	Tatjana Steybe	A randomized phase 2 proof-of-concept study to evaluate the efficacy and safety of topical bimiralisib application in patients suffering from actinic keratosis on the face and/or scalp and/or back of hands over a 2 and 4-week treatment period
Throughout	Helena Nammour	The Effect of Socioeconomic Status on Recurrence of Merkel Cell Carcinoma: A Propensity Score Matching Study
Throughout	Sarah Santos	Improving Skin Hydration, Barrier Integrity and Quality of Life in Brazilian Babies with Sensitive Skin: A Clinical Study on the use of an Oat-Based Wash and Moisturizer Regimen
Throughout	Angela Loczi-Storm	Exploring the Diagnostic Yield and Metastasis Detection in Sentinel Lymph Node Biopsies: A Retrospective Study of Melanoma Patients
Throughout	Kamil Taneja	Comprehensive analysis of Merkel cell carcinoma seasonality: a surgical event-based study

Late Breakers and Notable Presentations Information at AAD '25

Alopecia Areata and Hair Disorders (1/4)

Date	Author	Title
07 Mar 2025	Li-Chi Chen	No Increased Risk of Breast or Gynecologic Cancers in Women with 5a-Reductase Inhibitor Exposure for Female Pattern Hair Loss: A Population-Based Propensity Score-Matched Cohort Study
07 Mar 2025	Arash Mostaghimi	Timing of Initial Hair Regrowth and Clinical Trial-Defined Response: Results of an ALLEGRO 2b/3 Post-Hoc Analysis
08 Mar 2025	Justin Ko	Evidence of Undertreatment of Severe Alopecia Areata in Routine Clinical Practice with Baricitinib Therapy: Interim Results from a Prospective Observational Study
08 Mar 2025	Cristina Sicorschi Gutu	Low Dose Oral Minoxidil vs Topical Minoxidil for Androgenetic Alopecia: Systematic Review and Meta-Analysis of Randomized Controlled Trials
08 Mar 2025	Arash Mostaghimi	Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
09 Mar 2025	Jenny Lai	Timing of potassium monitoring in females treated for acne with spironolactone is not optimal: A retrospective cohort study
09 Mar 2025	Sonja Kobayashi	A retrospective cohort study of women with breast cancer presenting to hair loss clinic

Late Breakers and Notable Presentations Information at AAD '25

Alopecia Areata and Hair Disorders (2/4)

Date	Author	Title
09 Mar 2025	Nathália Borba	Combined Minoxidil and Platelet-Rich Plasma Compared With Monotherapy in Androgenetic Alopecia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Throughout	Dr Stephen	Vitamin D levels in Alopecia Areata : A cross-sectional study
Throughout	Paradi Mirmirani	Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials
Throughout	Ryan Chan	Impact of Low-Dose Oral Minoxidil on Blood Pressure in Androgenetic Alopecia Patients Concomitantly Taking Antihypertensive Medications: A Multi-Center Cohort Study
Throughout	Gia Tang BMedSci	The effect of sublingual minoxidil on androgenetic alopecia in transgender individuals receiving testosterone for gender-affirmation: A 24-week single-centre double-blinded, randomized, placebo-controlled clinical trial
Throughout	Xiangqian Li	Patient-reported quality of life, psychosocial and economic burden of alopecia areata in China: a multicenter cross-sectional study
Throughout	Brett King	Optimization of deuruxolitinib dosing in adult patients with alopecia areata: Results from a randomized, parallel-group, multicenter, Phase 2 trial

Late Breakers and Notable Presentations Information at AAD '25

Alopecia Areata and Hair Disorders (3/4)

Date	Author	Title
Throughout	Apichaya Ketyungyoenwong	A pilot study of efficacy and safety comparing 5% minoxidil emulsion and standard topical 5% minoxidil solution in the treatment of male androgenetic alopecia
Throughout	Maryanne Senna	Long-term efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata (AA): 3-year results from the ALLEGRO-LT phase 3, open-label study
Throughout	Kent Hanson PharmD	Timing of Patient-Reported Outcome Response and Clinical Response: Results of an ALLEGRO 2b/3 Post-Hoc Analysis
Throughout	Thierry Passeron	Impact of Eyebrow and Eyelash Hair Loss on Health-Related Quality of Life Among Patients with Alopecia Areata: Results From a Real-World Survey in 5 European Countries
Throughout	Olivia Ueltschi	An Interview-based Qualitative Study of Nail Changes in Cancer Patients
Throughout	Gabriel Gomes Lopes	Low-Level Laser Therapy with Minoxidil vs. Minoxidil Alone in Female Alopecia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Throughout	Abena Minta	An Interview-based Qualitative Study of Scalp Cooling, Alopecia, and Disparities in Breast Cancer Patients

Late Breakers and Notable Presentations Information at AAD '25

Alopecia Areata and Hair Disorders (4/4)

Date	Author	Title
Throughout	Funmilayo Ogunbufunmi	Demographic Differences in Anxiety and Depression in Women with Alopecia: A Retrospective Study
Throughout	Surya Khatri	Natural History of Patch Stage Alopecia Areata in a Large Cohort Study of U.S. Women

Late Breakers and Notable Presentations Information at AAD '25

Cosmetic and Aesthetic Dermatology (1/4)

Date	Author	Title
08 Mar 2025	Isabela Tollini Jones	Natural Results: How to Use Injectables for A Natural Look
09 Mar 2025	Alice Lin	Enhancing Interpreter Utilization Among Outpatient Dermatology Clinic Telephone Schedulers Assisting Patients with Limited English Proficiency: A Quality Improvement Study
Throughout	Savitha Rajagopal	Assessment of the benefits of an innovative chemical peel containing added biofunctionals for adults with acne-prone skin: an exploratory interventional study
Throughout	Catherine Queille Roussel	Fast and visible efficacy of a salicylic acid-based dermocosmetic cream in mild to moderate adult female acne subjects with fair skin phototypes: results from an exploratory split-face study
Throughout	Rebecca Barresi-Thornton	A Multi-Functional Post-Procedure Formulation that Enhances the Outcome of a Split-Face, Double Blinded Controlled Non-ablative Laser Study
Throughout	Ana Du	Evaluation of the Efficacy, Tolerance, and Satisfaction of a Bi-Phase Topical Skincare Serum for Intimate Skin Areas
Throughout	Joely Kaufman	Positive Relationship Between Cheek Smoothness Improvement and Fine Line Reduction: A Post Hoc Analysis of a Phase 3 Study on VYC-12L Treatment for Skin Quality

Late Breakers and Notable Presentations Information at AAD '25

Cosmetic and Aesthetic Dermatology (2/4)

Date	Author	Title
Throughout	Natalia Kovytkina	A novel bonding technology combining Maitake, Matrixyl, and Rhamnose stimulates the gene and protein expression of different collagens in fibroblasts: results from an in vitro study
Throughout	XI YAN	Enhancement of post-laser skin healing by a new topical regenerative cream in a blinded randomized controlled clinical trial
Throughout	Jihee Kim	A serum containing vitamins C, E, and ferulic acid enhanced skin photoaging sign correction after microneedling in a double-blind, placebo-controlled, split-face clinical trial
Throughout	Steven Weiner	SPLIT-FACE STUDY OF TWO HYALURONIC ACID FILLERS IN MIDFACE REJUVENATION: CLINICAL IMPLICATIONS
Throughout	Orit Markowitz	A comparative study evaluating the synergistic effects for midface improvement when pairing PLLA-SCA with a skincare regimen
Throughout	Woramate Bhorntarakcharoen	Preliminary findings on the study to evaluate efficacy and safety of Polynucleotide for facial ligaments and neck lifting in Thailand
Throughout	Sariya Sittivanaruk	The study to evaluate the efficacy and safety of using hyaluronic acid type VYC-12L injection for facial rejuvenation

Late Breakers and Notable Presentations Information at AAD '25

Cosmetic and Aesthetic Dermatology (3/4)

Date	Author	Title
Throughout	Renato Pinto Pharmacist	Evaluation of Collagen, elastin and Hyaluronic Acid Stimulation by a Serum with Niacinamide and DNA Repairing Actives: An In Vitro Study
Throughout	Joshua Kent	A Clinical Study on the Anti-Aging Benefits of a 10% Glycolic Acid and Vitamin B5 Topical Serum
Throughout	Jihee Kim	Fractional Microneedle Radiofrequency (RF) with Split-Neck Application of Vitamin C, E, and Ferulic Acid Serum vs. Placebo for Neck Skin Rejuvenation: A Placebo-Controlled Trial
Throughout	Glynis Ablon	Aesthetic Improvement with Liquid Relabotulinum-A Treatment in a 12-Month Randomized Controlled Trial Among Subjects with Moderate-to-Severe Glabellar Lines
Throughout	Joely Kaufman-Janette	RelaBoNT-A treatment of glabellar lines and lateral canthal lines of different baseline severity: subgroup analyses of pooled Phase III study data
Throughout	Nathan Shen	Efficacy and Safety of Glycopyrronium Cloths, a Novel Management for Hyperhidrosis at Amputation Sites: A Randomized Controlled Trial
Throughout	Shirley Sampaio	Improvement in Pigmentation and Skin Tone Uniformity after 28 and 56 Days of Use of a Multifunctional Facial Sunscreen with 2% Niacinamide: Clinical Outcomes and In Vitro Permeation Results

Late Breakers and Notable Presentations Information at AAD '25

Cosmetic and Aesthetic Dermatology (4/4)

Date	Author	Title
Throughout	Anderson Alves Costa Anderson Costa	Effect a moisturizing cream containing ceramides, hyaluronic acid and a slow-release delivery system in Brazilian patients with atopic dermatitis: an observational study
Throughout	Thierry Passeron	2-MNG-containing depigmenting serum is non-inferior to hydroquinone 4% in the treatment of facial melasma: a monocentric randomized controlled study
Throughout	Aaliyah Bourne	Comparative Efficacy of Microneedling with Tranexamic Acid Versus Vitamin C for Melasma: A Synthesis of Four Split-Face Clinical Trials
Throughout	Woramate Bhorntarakcharoen	The study to evaluate the efficacy and safety of using 532 nm potassium-titanyl-phosphate (KTP) laser for melasma treatment in Asians
Throughout	Carola Romanò	A prebiotic and panthenol-containing multipurpose healing dermocosmetic post cryotherapy for actinic keratoses: results of a randomized controlled trial
Throughout	Woraphong Manuskiatti	Long-term efficacy and safety of fractional 1064-nm picosecond laser for prophylaxis of post-mammoplasty scar in Asians: A prospective randomized controlled study
Throughout	Swagota Sen	Comparative study of safety and efficacy of intralesional bleomycin and cryotherapy on viral wart.

Late Breakers and Notable Presentations Information at AAD '25

Health Disparities and Access to Care (1/3)

Date	Author	Title
08 Mar 2025	Ehizogie Edigin	Analysis of Cutaneous Sarcoidosis Hospitalizations: A National United States Population Based Study
08 Mar 2025	Brandon Block	Rural-urban disparities in the use of FDA-approved steroid-sparing topical medications for inflammatory dermatologic conditions: A DataDerm study
08 Mar 2025	Isaac Sluder	Assessing the Education, Knowledge and Comfort Levels of Gender Affirming Care Providers Regarding the Dermatologic Manifestations of Gender Affirming Care: A cross-sectional study
09 Mar 2025	Martina J Porter	Strategies for Recruitment of a Diverse Patient Population for Dermatology Clinical Trials (Panel Discussion)
Throughout	Madison Olexson	Social Determinants of Health Associate with Incident Cutaneous Inflammatory Skin Disease: A retrospective cohort study using real-world data
Throughout	Alexander Gomez-Lara	Prevalence of Rosacea Phenotypes by Race, Ethnicity, and Gender: A Cross-Sectional Study of a Diverse Patient Cohort
Throughout	Ashley Houff	Hearing Impairment in Individuals with Port-Wine Stains and Sturge-Weber Syndrome: A Survey Study

Late Breakers and Notable Presentations Information at AAD '25

Health Disparities and Access to Care (2/3)

Date	Author	Title
Throughout	Mayuri Vaish B.A.	Comparative Analysis of Glucocorticoid Use in Flares of Cutaneous and Non-Cutaneous Systemic Lupus Erythematosus: A Retrospective Study
Throughout	Kareem Elhage	The Association Between Atopic Dermatitis and Obstructive Sleep Apnea: a Cross-Sectional Study Using the All of Us Database
Throughout	Sumir Chawla BMBS BMedSci (Hons) MRCP (UK) PGCERT AFHEA	Patient experience of teledermatology triage for skin cancer surgery: a cross-sectional study
Throughout	Matthew Viveiros	Gender, Rank, and Specialization as Key Predictors of Dermatologist Workload and Response Times to Patient Messages: A Cross-Sectional Study
Throughout	Shaliz Aflatooni	Assessing Satisfaction Levels with Teledermatology in the Post-COVID-19 Era: A Cross-Sectional Study
Throughout	Kathryn Xu	Implementing Skin of Color Education in Dermatology for Medical Students: A Single-Center Study
Throughout	Darshana Seeburruth	Evaluating the Impact of Novel Educational Modules on Canadian Medical Students' Confidence, Knowledge, and Diagnostic Accuracy in Skin of Colour Dermatology: A National Pilot Study

Late Breakers and Notable Presentations Information at AAD '25

Health Disparities and Access to Care (3/3)

Date	Author	Title
Throughout	Megan Hoang	The Value of Enhancing Dermatologic Care for Uninsured, Low-Income Patients: A Retrospective Study of a Dermatology Free Clinic
Throughout	Eli Raneses	Racial, Ethnic, and Phototype Reporting in Dermatology Clinical Trials From 2016 to 2024
Throughout	Manisha Vadali.	Disparities in Racial Representation in Hyperhidrosis Clinical Trials: A Focus on African American Inclusion
Throughout	Shreya Deoghare MBBS	Demographic and Socio-economic Characteristics of Skin Cancer Patients with Poor Lifestyle Factors: A BRFSS Study
Throughout	Raphaella Lambert	Rural-urban disparities in the use of targeted and non-targeted systemic medications for inflammatory dermatologic conditions: A DataDerm study
Throughout	Alim Osman.	Retrospective Analysis of Race/Ethnicity Representation in Trials Published by JAAD Between 2021-2024
Throughout	Sarah Brauer	High Prevalence of Incorrect and Unclear Terminology in Sex and Gender Reporting Across Dermatology Clinical Trials

Late Breakers and Notable Presentations Information at AAD '25

Environmental and Lifestyle Impact on Skin Health (1/2)

Date	Author	Title
08 Mar 2025	Aaron Gabriel W. Sandoval	Perspectives on the Importance of Environmental Factors and Resources in Dermatology Innovation: A Qualitative Study
08 Mar 2025	Nargiza Sadr	Thyroid Function and Benzophenone-3 in Sunscreen: A Nationwide Study
08 Mar 2025	Li-Chi Chen	Protective Effects of Long-Term Narrowband Ultraviolet B Phototherapy against Cardiometabolic Diseases in Patients with Vitiligo: A Retrospective Propensity Score-Matched Cohort Study
08 Mar 2025	Maxine Joly-Chevrier	Elucidating the Environmental, Socioeconomic, and Occupational Risk Factors of Psoriasis: the ESO-PsO Study
Throughout	Kaushik Venkatesh	U.S. Food and Drug Administration recalls of cosmetic and personal products from 2011 to 2023: A cross-sectional study
Throughout	Joseph F. Merola	Long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: Updated results from phase 2b/3 studies and their open-label extensions
Throughout	Ji Su Lee	Early-life diet and persistent atopic dermatitis: A nationwide cohort study

Late Breakers and Notable Presentations Information at AAD '25

Environmental and Lifestyle Impact on Skin Health (2/2)

Date	Author	Title
Throughout	Gunnar Mattson	Atopic Dermatitis Patient Experiences with Climate Change Impacts: A Cross-Sectional Survey Study
Throughout	Jonathan Silverberg	Impact of Atopic Eczema on Life Choices and Destiny: A Global Study
Throughout	Yayoi Tada	Effectiveness and Safety Data of Dupilumab in Asian Adult Patients With Atopic Dermatitis are Consistent With the Overall Global Population: Real-World Insights 2 Years Into the GLOBOSTAD Multinational Prospective Observational Study
Throughout	Brandon Ansbro	The heterogeneous characteristics of itch vary by atopic dermatitis severity and differentially impact mental health, sleep, and quality of life in children and adults: A prospective cohort study
Throughout	Xinxin Wu	Obesity and Related Comorbidities on the Prevalence of Self-Reported Skin Allergy: NHIS Study
Throughout	Jessica Emerson	Associations between daily itch and quality of life in dermatology trials
Throughout	Richard G. Langley	Body Mass Index and Weight as Cardiometabolic Outcomes in Pediatric Patients With Moderate-to-Severe Plaque Psoriasis Treated With Apremilast: 16-Week Results From the SPROUT Randomized Controlled Trial



Key Sponsored Symposia Information (Industry and non industry)



AAD 2025 Key Industry Sponsored Symposia Information (1/4)

Date	Sponsor	Title
06 Mar 2025	LEO Pharma	Chronic Hand Eczema: A New Day is at Hand
06 Mar 2025	Beiersdorf	THIAMIDOL: A Breakthrough Innovation in Dark Spot Correction
06 Mar 2025	Medscape / AbbVie	"Inside Psoriasis: A Focus on Advanced, Targeted Systemic Therapy"
06 Mar 2025	Medscape / AbbVie	Segment 1 – The Psoriasis Snapshot: Rapid-Fire Recap on Recently Presented Data
06 Mar 2025	Medscape / AbbVie	Segment 2 – Breakaway: Perspectives From the Streets Segment 3 – IPC Consensus in Context Segment 4 – Special Report With a Patient Segment 5 – What Does Clear Mean for Patients?
06 Mar 2025	Medscape / AbbVie	"Elevating Care in Moderate to Severe Atopic Dermatitis: Case Challenges"
08 Mar 2025	Pfizer	Understanding Vitiligo: Exploring the Patient Experience





AAD 2025 Key Industry Sponsored Symposia Information (2/4)

Date	Sponsor	Title
08 Mar 2025	El Lilly	Clarifying Pathways in the Treatment of Atopic Dermatitis with Biologics
08 Mar 2025	Johnson & Johnson	The Patient's Voice: Guiding the Path to Address Unmet Needs in Psoriasis
08 Mar 2025	Sanofi / Regenerol	What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
08 Mar 2025	Sanofi / Regenerol	How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
08 Mar 2025	Sanofi / Regenerol	Under the Itchy Surface: The Insidious Cumulative Burden of Type 2 Inflammation in AD
08 Mar 2025	Sanofi / Regenerol	The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in PN
08 Mar 2025	Sanofi / Regenerol	Inside the Hive: Type 2 Inflammatory Pathways in CSU





AAD 2025 Key Industry Sponsored Symposia Information (3/4)

Date	Sponsor	Title
08 Mar 2025	Sanofi / Regeneron	Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in BP
09 Mar 2025	Regeneron	Narrowing Nonmelanoma Skin Cancer Gaps With Neoadjuvant Immunotherapy: Multidisciplinary Strategies for Success
09 Mar 2025	Regeneron	Why Use Immunotherapy in the Neoadjuvant Setting for Nonmelanoma Skin Cancer? Incorporating Multiple Perspectives
09 Mar 2025	Regeneron	Understanding the Efficacy Data for Neoadjuvant Immunotherapy: Focus on Cutaneous Squamous Cell Carcinoma
09 Mar 2025	Regeneron	Basal Cell Carcinoma and Beyond: Which Patients Might Benefit Most From Neoadjuvant Immunotherapy?
09 Mar 2025	Regeneron	Practical, Interdisciplinary Strategies to Integrate Immunotherapy Early Into Nonmelanoma Skin Cancer Treatment
09 Mar 2025	Regeneron	Enhancing the Safety of Patients on Immunotherapy: Multidisciplinary Insights

AAD 2025 Key Industry Sponsored Symposia Information (4/4)



Date	Sponsor	Title
09 Mar 2025	Sanofi	Atopic Dermatitis Pathway Pursuit: The OX40-Ligand Edition
09 Mar 2025	Blueprint Medicines	Could You Be Missing Systemic Mastocytosis? The Role of the Dermatologist

AAD 2025 Key Non-Industry Sponsored Symposia Information (1/6)



Date	Author	Title
06 Mar 2025	Dr. Raj Chovatiya Dr. Linda Stein Gold	CHRONIC HAND ECZEMA: A NEW DAY IS AT HAND
06 Mar 2025	Dr. Firas Al-Niaimi Dr. Ludger Kolbe	THIAMIDOL: A BREAKTHROUGH INNOVATION IN DARK SPOT CORRECTION
06 Mar 2025	Bruce Strober Jason E. Hawkes	INSIDE PSORIASIS: A FOCUS ON ADVANCED, TARGETED SYSTEMIC THERAPY
06 Mar 2025	Lakshi Aldredge Peter Lio	ELEVATING CARE IN MODERATE TO SEVERE ATOPIC DERMATITIS: CASE CHALLENGES
07 Mar 2025	Trilokraj Tejasvi George Han	TECHNOLOGY IN DERMATOLOGY: TAILORING SOLUTIONS TO YOUR PRACTICE AND OPTIMIZING JOY & IMPACT
07 Mar 2025	Ethan A. Lerner Brian S Kim	CHRONIC PRURITUS: BEDSIDE TO BENCH PERSPECTIVES
07 Mar 2025	C. William Hanke Jeanine B. Downie	PEARLS FROM THE MASTERS OF DERMATOLOGICAL SURGERY



AAD 2025 Key Non-Industry Sponsored Symposia Information (2/6)



Date	Author	Title
07 Mar 2025	Carolyn Goh Michelle B Tarbox	ALOPECIA: WORK-UP AND TREATMENT
07 Mar 2025	Alan D. Irvine Dawn Eichenfield	HOT TOPICS IN PEDIATRIC DERMATOLOGY
07 Mar 2025	Brett King Julien Seneschal	JAK INHIBITORS: A NEW FRONTIER IN DERMATOLOGY
07 Mar 2025	Alina G. Bridges Antoanella Calame	CLINICOPATHOLOGIC SELF-ASSESSMENT
07 Mar 2025	Jerry Shapiro Lidia Rudnicka	UPDATES IN HAIR DISORDERS
07 Mar 2025	Mariana Ramirez Randy Ko	GROSS AND MICROSCOPIC SYMPOSIUM
07 Mar 2025	Divya Sharma Maria K. Hordinsky	COMPREHENSIVE HAIR RESTORATION USING SURGICAL AND NON-SURGICAL TECHNOLOGIES



AAD 2025 Key Non-Industry Sponsored Symposia Information (3/6)



Date	Author	Title
07 Mar 2025	Roy G. Geronemus Dieter Manstein	NEW INNOVATIONS IN DERMATOLOGY: WHAT DEVICES YOU WILL BE USING IN THE NEXT 1-5 YEARS
07 Mar 2025	Michael Tetzlaff Caroline C. Kim	TRANSLATING EVIDENCE INTO PRACTICE: PRIMARY CUTANEOUS MELANOMA GUIDELINES
07 Mar 2025	Emily Y. Chu David Cotter	THE 2025 DEBATES: CONTROVERSIES IN DERMATOLOGY
07 Mar 2025	Yvonne Chiu Leslie Castelo-Soccio	TREATING SEVERE SKIN DISEASES IN CHILDREN
08 Mar 2025	Bianca Maria Piraccini Jerry Shapiro	HAIR LOSS FROM TRICHOSCOPY TO THERAPY
08 Mar 2025	Bruce Elliot Strober Richard G. B. Langley	PSORIASIS: MODERN THERAPEUTIC APPROACHES
08 Mar 2025	Emma Guttman Mark Lebwohl	INFLAMMATORY SKIN DISEASES: THE TRANSLATIONAL REVOLUTION



AAD 2025 Key Non-Industry Sponsored Symposia Information (4/6)



Date	Author	Title
08 Mar 2025	Kimberly Marie Ken Ramin Fathi	DERMATOLOGIC SURGERY PEARLS: OPTIMIZING SAFETY, SATISFACTION, EFFICIENCY
08 Mar 2025	Jeffrey P. North Iwei Yeh	WHAT'S NEW IN DERMATOPATHOLOGY
08 Mar 2025	Naomi Lawrence Henry Pierce Heaton	DERMATOLOGY REVIEW: SKIN CANCER, SURGICAL, AND COSMETIC
08 Mar 2025	Denise W Metry Eulalia Baselga Torres	CHALLENGING ADULT AND PEDIATRIC AUTOIMMUNE CONNECTIVE TISSUE DISEASE CASES: PEARLS FOR DIAGNOSIS AND MANAGEMENT
08 Mar 2025	Deepti Gupta Maria Cecilia Garzon	VASCULAR ANOMALIES SYMPOSIUM: CLASSIFICATION, CLINICAL CHALLENGES, AND MANAGEMENT UPDATE
08 Mar 2025	Eric Simpson Victoria Werth	WHAT WENT WRONG? HOW DYSREGULATED TYPE 2 IMMUNITY CONTRIBUTES TO AD, PN, CSU, AND BP
08 Mar 2025	Iltefat Hamzav David Rosmarin	UNDERSTANDING VITILIGO: EXPLORING THE PATIENT EXPERIENCE



AAD 2025 Key Non-Industry Sponsored Symposia Information (5/6)



Date	Author	Title
08 Mar 2025	Gil Yosipovitch Jonathan Silverberg	<u>CLARIFYING PATHWAYS IN THE TREATMENT OF ATOPIC DERMATITIS WITH BIOLOGICS</u>
08 Mar 2025	Carl Streed Jon Klint Peebles	<u>LGBTQ/SGM HEALTH IN DERMATOLOGY: ESSENTIALS AND UPDATES</u>
08 Mar 2025	Martina J Porter Thy Nhat Huynh	<u>THE QUALITY IMPROVEMENT AND INNOVATION SYMPOSIUM</u>
08 Mar 2025	Haley Naik Christopher John Sayed	<u>HIDRADENITIS SUPPURATIVA/ACNE INVERSA (HS/AI): CURRENT MEDICAL AND SURGICAL MANAGEMENT</u>
09 Mar 2025	Jerry Shapiro Brett King	<u>ALOPECIA AREATA: NEW THERAPIES</u>
09 Mar 2025	David M. Miller Vishal A. Patel	<u>NARROWING NONMELANOMA SKIN CANCER GAPS WITH NEOADJUVANT IMMUNOTHERAPY: MULTIDISCIPLINARY STRATEGIES FOR SUCCESS</u>
09 Mar 2025	Raj Chovatiya Mona Shahriari	<u>ATOPIC DERMATITIS PATHWAY PURSUIT: THE OX40-LIGAND EDITION</u>



AAD 2025 Key Non-Industry Sponsored Symposia Information (6/6)



Date	Author	Title
09 Mar 2025	Lauren Madigan Jason Hawkes	COULD YOU BE MISSING SYSTEMIC MASTOCYTOSIS? THE ROLE OF THE DERMATOLOGIST
10 Mar 2025	Steven T. Chen Lindsay Chaney Strowd	CONSULTATIVE DERMATOLOGY FOR THE HOSPITALIZED PATIENT
10 Mar 2025	Suzanne L Kilmer Arielle N.B. Kauvar	WHAT'S NEW AND WHAT'S TRUE FOR ENERGY BASED DEVICES IN DERMATOLOGY
10 Mar 2025	Alisa Femia David A. Wetter	CUTANEOUS LUPUS AND DERMATOMYOSITIS: MANAGEMENT PEARLS AND PITFALL FOR THE GENERAL DERMATOLOGIST
10 Mar 2025	Kristen Irene Lo Sicco Loren Krueger	FOLLICULAR RESCUE IN SCARRING ALOPECIAS: TREATING TO HALT DISEASE PROGRESSION AND GROW HAIR
10 Mar 2025	Courtney Reynolds Schadt Jean L Bologna	SKINTERNAL MEDICINE: AN UPDATE ON CUTANEOUS MANIFESTATIONS OF SYSTEMIC DISEASE



Noteworthy AI / ML presentations at AAD 2025





Themes from key AI / ML presentations at AAD 2025 (1/2)

- **AAD 2025 will reflect how AI is transforming dermatology by enhancing diagnostic accuracy, streamlining clinical workflows, and advancing drug discovery, but its integration demands robust ethical frameworks and transparent patient communication**
- Check out the key AI / ML themes at AAD 2025 below:
 - **AI for Diagnostic Accuracy and Early Detection in Dermatology:**
 - Sessions will emphasize **AI's potential to enhance diagnostic precision for skin cancer and inflammatory diseases**. Research will highlight AI models' ability to differentiate between benign and malignant lesions, enabling earlier detection and more personalized treatment strategies
 - **AI in Hair, Scalp Disorders, and Wound Care Management:**
 - Presentations will explore AI-powered diagnostic tools for alopecia and scalp conditions. **Findings will focus on machine learning algorithms that improve identification of hair disorders, optimizing treatment pathways and enhancing patient outcomes**



Themes from key AI / ML presentations at AAD 2025 (2/2)

- **AI in Wound Care and Management:**

- Sessions will highlight the integration of AI-driven hyperspectral imaging for advanced wound care, offering objective assessments of tissue types. Studies will showcase AI's ability to refine treatment strategies and accelerate healing processes

- **Ethical and Regulatory Aspects of AI:**

- Discussions will focus on transparency tools for AI decision systems in dermatology. Experts will address the ethical challenges and regulatory requirements essential for the safe deployment of AI in clinical practice

- **AI for Drug Discovery and Education:**

- Presentations will cover AI-generated drug candidates with biologics-like efficacy for psoriasis and other conditions. Sessions will also highlight AI's role in advancing dermatology education through AI-generated modules and diagnostic simulations



Noteworthy AI / ML presentations at AAD 2025

Notable Presentations Information At AAD 2025

AI / ML (1/5)



Date	Author	Title
07 Mar 2025	Yingjoy Li	Developing transparency tools for the oversight of medical AI decisioning systems in dermatology: A case study on skin lesion analyzers
07 Mar 2025	Juwon Lee	Are Pictures Worth a Thousand Words? Not When Training AI for Alopecia Diagnosis
07 Mar 2025	Yevgeniy Semenov Shannon Wongvibulsin	Applications of Artificial Intelligence in Dermatology - Part 1 and Part 2
07 Mar 2025	Fatih Goktay	Artificial Intelligence (AI) and the Diagnosis of Nail Disorders
07 Mar 2025	Devin Barzallo	Comparative Diagnostic Accuracy Study of AI Chatbots in Diagnosing Skin Cancer Subtypes
08 Mar 2025	Sophia Luyten	A Machine Learning Model for Early Detection of Mycosis Fungoides: Distinguishing CTCL from Benign Dermatoses
08 Mar 2025	Nicholas Muller	Pathologist consensus is crucial for the development of artificial intelligence training data in dermatology.

Notable Presentations Information At AAD 2025

AI / ML (2/5)



Date	Author	Title
08 Mar 2025	Dilraj Kalsi	A Multi-Centre Clinical Performance Review of an Artificial Intelligence as a Medical Device in Excluding a Diagnosis of Melanoma in Urgent Suspected Skin Cancer Pathways
08 Mar 2025	Kiran Motaparathi	Updates in Artificial Intelligence/Computer Assisted Diagnosis
09 Mar 2025	Maria K. Hordinsky	Artificial intelligence updates for the hair loss clinics
09 Mar 2025	Allison Yan	Development of a machine learning model to increase accuracy of cellulitis diagnosis
10 Mar 2025	Faranak Kamangar	The Tech Arms Race: How can Tech & AI Solutions Support PA and Practice Administrative Burdens?
10 Mar 2025	Jane Margaret Grant-Kels	Ask the Dermatoethicist! What are ethical considerations relevant for prior authorizations and the use of technology and AI to support PAs?
10 Mar 2025	Shannon Wongvibulsin	What AI Can Do for Us Now

Notable Presentations Information At AAD 2025

AI / ML (3/5)



Date	Author	Title
10 Mar 2025	Zhuo Ran Cai	THE FUTURE IS NOW: A BOOTCAMP IN ARTIFICIAL INTELLIGENCE
Throughout	Shannon K. Moran	Objective scoring of dermatochalasis using artificial intelligence
Throughout	Kaitlyn Ramsay	Hyperspectral Imaging for Advanced Wound Care: Integrating AI and Bacterial Quantification Techniques
Throughout	Madeline Fitzhugh	What a Hand Can Tell Us: Artificial Intelligence to Predict the Age of a Hand
Throughout	Shangyi Fu	Assessing the Accuracy of ChatGPT in Answering Dermatology-Related Patient Questions: Implications for AI Integration in Clinical Practice
Throughout	Aneri Patel	A Comparative Analysis of AI Models in Dermatology
Throughout	Kelsey Ouyang	Limitations of quantum artificial intelligence for enhanced skin cancer diagnosis: A scoping review

Notable Presentations Information At AAD 2025

AI / ML (4/5)



Date	Author	Title
Throughout	Ahmad Alamari AA	Evaluation of Artificial Intelligence Chatbots in Addressing Most Searched Queries on Psoriasis
Throughout	Ndanzia Mpunga	Patient Perspective on the use of Artificial Intelligence for Image-Based Algorithms: A Cross-Sectional Survey
Throughout	Nneka Ede	Development of a Scalp and Hair Disease Imaging Dataset for Machine Learning Classification of Central Centrifugal Cicatricial Alopecia
Throughout	Sarah Kooper-Johnson	Image Generation of Common Dermatological Diagnoses by Artificial Intelligence; Evaluation of the Potential for Education and Training Purposes
Throughout	Jonathan C. Hwang	Empowering dermatology through artificial intelligence education
Throughout	Juwon Lee	Are Pictures Worth a Thousand Words? Not When Training AI for Alopecia Diagnosis
Throughout	Yannis Cattan	Stratification of the Continuum of Skin Immune-Mediated and Inflammatory Diseases via an AI Foundation Model

Notable Presentations Information At AAD 2025

AI / ML (5/5)



Date	Author	Title
Throughout	Amber Loren King	A Comparison of Machine Learning Algorithms Using Melanoma Primary Tumor Somatic Mutations to Predict Lymph Node Metastasis
Throughout	Devin Barzallo	Comparative Diagnostic Accuracy Study of AI Chatbots in Diagnosing Skin Cancer Subtypes
Throughout	Chris Li	Oral IL-17A Small Molecule Inhibitors Designed by Generative AI with Biologics-Like Potency for Psoriasis Treatment
Throughout	Samiha Mohsen	Comparing Clinicians' Assessments of Wound Tissue Types to an AI Model: Implications for Wound Care Practice
Throughout	Robert Swerlick	USING ARTIFICIAL INTELLIGENCE FOR RARE DERMATOLOGIC DISEASES: GETTING THE RIGHT PATIENTS THE RIGHT TREATMENT AT THE RIGHT TIME



Strategic Insights and Strategy Development is our focus

COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM